diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 329db7879..89900ce3c 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -19,22 +19,28 @@ The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive pric ### Additional Evidence (extend) -*Source: [[2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations]] | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5* +*Source: 2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5* Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients. ### Additional Evidence (extend) -*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15* +*Source: 2025-06-01-cell-med-glp1-societal-implications-obesity | Added: 2026-03-15* The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category. ### Additional Evidence (extend) -*Source: [[2025-03-01-medicare-prior-authorization-glp1-near-universal]] | Added: 2026-03-15* +*Source: 2025-03-01-medicare-prior-authorization-glp1-near-universal | Added: 2026-03-15* MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems. + +### Additional Evidence (challenge) +*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16* + +SELECT trial cost-effectiveness analysis shows semaglutide achieves $32,219/QALY at 48% rebated prices (highly cost-effective) versus $136,271/QALY at list price (marginally cost-effective). Medicare deal at $245/month represents 82% price reduction. The inflationary impact claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at negotiated net prices, and recent price trajectory suggests faster-than-expected flip to cost-effectiveness. + --- Relevant Notes: diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index 1222d36b5..c8856e293 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr - Nature Medicine: additive benefits with SGLT2 inhibitors - First GLP-1 to receive FDA indication for CKD in T2D patients + +### Additional Evidence (confirm) +*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16* + +SELECT trial modeling shows multi-organ savings hierarchy: T2D prevention $14,431, CKD prevention $2,074, CV event prevention $1,512 per subject lifetime. The compounding value exists but is heavily weighted toward metabolic protection (diabetes + kidney = $16,505) versus cardiovascular ($1,512). + --- Relevant Notes: diff --git a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md index 5299ec097..73e08fb4c 100644 --- a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md +++ b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md @@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, - FDA indication expansion to T2D patients with CKD (2024) - Dialysis cost benchmark: $90K+/year per patient + +### Additional Evidence (extend) +*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16* + +SELECT trial economic modeling quantifies CKD prevention savings at $2,074 per subject lifetime, which is 1.4x the CV event savings ($1,512) but only 14% of the diabetes prevention savings ($14,431). The kidney protection value is real but secondary to metabolic disease prevention in the economic hierarchy. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.json b/inbox/archive/.extraction-debug/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.json new file mode 100644 index 000000000..e3d8a5c2c --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-cost-effectiveness-is-price-dependent-with-rebated-prices-achieving-32k-per-qaly-versus-136k-at-list-price.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "glp-1-diabetes-prevention-savings-exceed-cardiovascular-savings-by-10x-making-metabolic-protection-the-primary-economic-lever.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "glp-1-cost-effectiveness-is-price-dependent-with-rebated-prices-achieving-32k-per-qaly-versus-136k-at-list-price.md:set_created:2026-03-16", + "glp-1-diabetes-prevention-savings-exceed-cardiovascular-savings-by-10x-making-metabolic-protection-the-primary-economic-lever.md:set_created:2026-03-16" + ], + "rejections": [ + "glp-1-cost-effectiveness-is-price-dependent-with-rebated-prices-achieving-32k-per-qaly-versus-136k-at-list-price.md:missing_attribution_extractor", + "glp-1-diabetes-prevention-savings-exceed-cardiovascular-savings-by-10x-making-metabolic-protection-the-primary-economic-lever.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.md b/inbox/archive/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.md index 73cfb598d..12e0ead83 100644 --- a/inbox/archive/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.md +++ b/inbox/archive/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.md @@ -7,9 +7,13 @@ date: 2025-01-01 domain: health secondary_domains: [internet-finance] format: paper -status: unprocessed +status: enrichment priority: medium tags: [glp-1, semaglutide, cost-effectiveness, cardiovascular, SELECT-trial, QALY] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -43,3 +47,10 @@ Cost-effectiveness analysis of semaglutide 2.4mg based on SELECT trial data, mod PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: Cost-effectiveness is price-dependent — the declining price trajectory may flip GLP-1s from inflationary to cost-effective faster than the existing claim anticipates EXTRACTION HINT: Focus on the price sensitivity of the cost-effectiveness conclusion and how recent price deals change the math + + +## Key Facts +- SELECT trial per 100,000 subjects (lifetime): 2,791 non-fatal MIs avoided, 3,000 revascularizations avoided, 487 strokes avoided, 115 CV deaths avoided +- Average per-subject lifetime treatment cost: $47,353 +- Australian analysis: at A$4,175/year, ICER = A$96,055/QALY (~US$138K/QALY), not cost-effective at A$50K threshold +- ICER 2025: semaglutide would need 80% price reduction to meet standard threshold at list price